Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received an average recommendation of “Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $17.56.

A number of equities research analysts recently weighed in on the company. Oppenheimer raised their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Finally, Needham & Company LLC decreased their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday.

Trevi Therapeutics Trading Down 2.1 %

TRVI opened at $6.47 on Tuesday. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39. The business’s fifty day simple moving average is $4.60 and its 200-day simple moving average is $3.75. The company has a market capitalization of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. On average, equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 24.37% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. raised its stake in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Trevi Therapeutics in the fourth quarter worth about $17,099,000. Vivo Capital LLC raised its position in Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock valued at $14,370,000 after acquiring an additional 1,875,000 shares in the last quarter. Woodline Partners LP raised its position in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after acquiring an additional 2,606,370 shares in the last quarter. Finally, MPM Bioimpact LLC raised its position in Trevi Therapeutics by 101.2% during the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock valued at $12,751,000 after acquiring an additional 1,556,379 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.